Prognose

Das durchschnittliche Kursziel der Analysten beträgt +8,47€(+193,08%). Der Median liegt bei +8,47€(+193,08%).

Kaufen	2
Halten	2
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	3 / 18
Levermann-Strategie	-3 / 13

News

12,701 Shares in Galecto, Inc. (NASDAQ:GLTO) Bought by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Galecto, Inc. (NASDAQ:GLTO – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,701 shares of the company’s stock, valued at approximately $59,000. Squarepoint Ops LLC owned approximately 0.96% of Galecto at the end of the most recent quarter. Galecto Trading Up 2.1% Shares of GLTO stock opened at $3.36 on Wednesday. Galecto, Inc. has a 12 month low of $2.01 and a 12 month high of $16.07. The company has a market cap of $4.44 million, a P/E ratio of -0.18 and a beta of 1.32. The firm has a fifty day moving average price of $2.82 and a 200 day moving average price of $4.13. Galecto (NASDAQ:GLTO – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.92) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Galecto, Inc. will post -15.91 EPS for the current year. Galecto Profile (Free Report) Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.» Mehr auf defenseworld.net
Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.» Mehr auf globenewswire.com
Galecto Reports Full-Year 2024 Financial Results
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte GALECTO INC. DL-,00001 einen Umsatz von 0,00€ und ein Nettoeinkommen von −2,34 Mio€

(EUR)	März 2025	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−2,34 Mio	53,86%
EBITDA	−2,40 Mio	54,05%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+3,82 Mio€
Anzahl Aktien	1,32 Mio
52 Wochen-Hoch/Tief	+13,62€ - +1,70€
Dividenden	Nein
Beta	1,32
KGV (PE Ratio)	−0,24
KGWV (PEG Ratio)	−0,01
KBV (PB Ratio)	+0,33
KUV (PS Ratio)	0,00

Unternehmensprofil

Galecto, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und entwickelt Moleküle für die Behandlung von Fibrose, Krebs, Entzündungen und anderen damit verbundenen Krankheiten. Der führende Produktkandidat des Unternehmens ist GB2064, der sich in Phase IIa für die Behandlung von Myelofibrose befindet. Darüber hinaus entwickelt es GB0139, einen inhalativen Galektin-3-Inhibitor, der sich in der klinischen Phase IIb zur Behandlung schwerer fibrotischer Lungenerkrankungen befindet, wie z. B. der idiopathischen Lungenfibrose, einer lebensbedrohlichen progressiven fibrotischen Erkrankung der Lunge, sowie GB1211, einen selektiven oralen Galektin-3-Inhibitor, der sich in der Phase IIa zur Behandlung von Krebs sowie in der Phase Ib/IIa zur Behandlung von Fibrose befindet. Galecto, Inc. wurde im Jahr 2011 gegründet und hat seinen Sitz in Boston, Massachusetts.